PLEASANTON, Calif., Aug. 13, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that industry leaders from AbbVie, Astellas, Eikon Therapeutics, Merck & Co., Moderna, and Roche will keynote at the upcoming 2024 Veeva R&D and Quality Summit in Boston on Sept. 9-10. Professionals across life sciences will come together to discuss how connected systems across clinical, regulatory, safety, and quality can move the industry forward for the benefit of patients.
Veeva R&D and Quality Summit is one of the largest life sciences events, drawing more than 2,000 executives to network and learn across more than 100 sessions. Veeva CEO Peter Gassner headlines the opening keynote, sharing innovations and examples of how connected data and systems can significantly streamline drug development and accelerate product time to market. Additional featured keynotes and sessions include:
"Veeva is committed to customer success, delivering integrated software, data, and services that can advance innovation for patients in need," said Jim Reilly, vice president of Veeva Development Cloud strategy. "Veeva R&D and Quality Summit brings the industry together to share learnings, fresh ideas, and new strategies to improve collaboration and accelerate the delivery of novel products."
The event is open exclusively to life sciences professionals. Register and stay up to date on the agenda at veeva.com/Summit.
Additional Information
Register for Veeva R&D and Quality Summit: veeva.com/Summit/register
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$281.35 |
Daily Change: | -2.85 -1.00 |
Daily Volume: | 982,787 |
Market Cap: | US$45.980B |
July 23, 2025 June 25, 2025 June 11, 2025 June 04, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load